

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

FEB 28 2005  
PARENT & TRADEMARKS  
16pt

**Effective on 12/08/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**

# **FEE TRANSMITTAL For FY 2005**

Applicant claims small entity status. See 37 CFR 1.27

<b>TOTAL AMOUNT OF PAYMENT</b>	<b>(\$)</b> <b>0.00</b>
--------------------------------	-------------------------

<b>Complete if Known</b>	
Application Number	10/070,532
Filing Date	March 7, 2002
First Named Inventor	Daniel R. Soppet
Examiner Name	C. J. Nichols
Art Unit	1647
Attorney Docket No.	PF168P3

**METHOD OF PAYMENT** (check all that apply)

Check     Credit Card     Money Order     None     Other (please identify): \_\_\_\_\_

Deposit Account    Deposit Account Number: 08-3425    Deposit Account Name: Human Genome Sciences, Inc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below     Charge fee(s) indicated below, except for the filing fee

Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17     Credit any overpayments

**FEES CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

<b>Application Type</b>	<b>FILING FEES</b>		<b>SEARCH FEES</b>		<b>EXAMINATION FEES</b>		
	<b>Fee (\$)</b>	<b>Small Entity</b>	<b>Fee (\$)</b>	<b>Small Entity</b>	<b>Fee (\$)</b>	<b>Small Entity</b>	<b>Fees Paid (\$)</b>
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Plant	200	100	300	150	160	80	_____
Reissue	300	150	500	250	600	300	_____
Provisional	200	100	0	0	0	0	_____

**2. EXCESS CLAIM FEES****Fee Description**

Each claim over 20 (including Reissues)

<b>Small Entity</b>	
<b>Fee (\$)</b>	<b>Fee (\$)</b>

50      25

Each independent claim over 3 (including Reissues)

200      100

Multiple dependent claims

360      180

<b>Total Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	<b>Multiple Dependent Claims</b>	
				<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>
23	- 45 =	x	=	_____	_____
5	- 7 =	x	=	_____	_____

**3. APPLICATION SIZE FEE**


If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<b>Total Sheets</b>	<b>Extra Sheets</b>	<b>Number of each additional 50 or fraction thereof</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>
_____	- 100 =	/50 (round up to a whole number) x	_____	= _____

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): \_\_\_\_\_

<b>SUBMITTED BY</b>	
Signature	
Name (Print/Type)	Kenley K. Hoover

**VIA HAND DELIVERY FEBRUARY 28TH, 2005**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: Soppet et al.

Confirmation No.: 5548

Application No.: 10/070,532

Group Art Unit: 1647

Filed: March 7, 2002

Examiner: Nichols, Christopher J.

For: Human Neuropeptide Receptor

Atty. Dkt. No. PF168P3

**REPLY AND AMENDMENTS UNDER 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir or Madam:

In response to the Office Action mailed November 1, 2004, please consider the following amendments and remarks. Applicant submits concurrently herewith: (a) a legible copy of page 38 of the specification as originally filed; (b) a Statement by Attorney for Applicant Regarding Permanence and Availability of Deposited Plasmids; (c) a petition for extension of time one month up to and including March 1, 2005; and (d) a Fee Transmittal, together with the appropriate fee(s).

Prior to further examination, Applicant respectfully requests entry of the following amendments.

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.
- Remarks begin on page 6 of this paper.